FK-037, a new parenteral cephalosporin, was tested against 483 organisms from clinical infections to establish preliminary susceptibility testing criteria with 30-jig disks. The proposed breakpoint zone diameters were -17 mm (MIC correlate, .8 ,ug/ml) for the susceptible category and <13 mm (MIC correlate, .32 ,ug/ml) for the resistant category. These interpretive guidelines produced no very major (false-susceptible) errors, 2.9% major (false-resistant) errors, and 6.2% minor errors for a total absolute agreement between methods of 90.9%.
The so-called fourth-generation cephalosporins such as cefclidine (formerly E-1040), cefepime, cefpirome, and cefquinome generally have a quarternary ammonium substitution at the C-3 position that enhances their activities against Bush group 1 ,B-lactamase-producing bacilli (1) (2) (3) (4) (9) (10) (11) . FK-037 is a new drug in this class; it has a 1-hydroxyethyl-5 aminopyrazole group at the C-3 position (1, 5, (9) (10) (11) . Its potency and spectrum of activity have been described to be similar to those of cefepime and cefpirome, which significantly inhibit all species of members of the family Enterobacteriaceae, Pseudomonas aeruginosa, oxacillin-susceptible staphylococci, Streptococcus spp., Haemophilus spp., Moraxella spp., and pathogenic Neisseria spp.; but it lacks broad-spectrum coverage of gramnegative anaerobes (1, 9) .
The initial pharmacology of FK-037 in humans revealed a maximum concentration in serum of 121 p.g/ml following a 2-g infusion (1 h) and an elimination half-life of 2.3 h (5, 9a). These pharmacokinetic features are comparable to those of cefepime and cefpirome; these agents are administered twice daily, and a susceptible breakpoint of .8 pug/ml for these agents has been recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (7, 8) (7) and the broth microdilution (8) methods. The methods, the number of strains tested, and the analyses conformed to the guidelines found in tentative guideline M23-T2 of NCCLS (6) . Strains that contributed false-susceptible (very major) or false-resistant (major) errors were repeat tested by both methods to ensure the reproducibility of the interpretive discrepancy. The reproducible errors were plotted (Fig. 1) Table 2 lists the species resistant to FK-037 and the frequency of resistant strains within each species.
The false-resistant, major interpretive errors were among oxacillin-resistant Staphylococcus aureus (ORSA; three strains), enterococci (nine strains), and one strain each of Staphylococcus simulans and Achromobacter xylosoxidans. Since ORSA isolates are considered resistant to cephalosporins and the enterococci are not recommended for routine testing by NC-CLS, the error rate cited above would be greater than expected in routine clinical laboratories. Many laboratories, however, test these species against the cephalosporins but do not report the results. The deletion of ORSA and enterococcal strains from the analyses markedly reduced the error to only 3.3% minor errors and 0.7% major errors (96.0% absolute agreement). Also, the choice of the optimal interpretive criteria for the disk diffusion test was not affected by testing these grampositive species.
Results of the present study indicate that 30-,ug FK-037 disks can be used to predict susceptibilities with accuracies comparable to the FK-037 MICs obtained by the reference broth microdilution method. Because this new broad-spectrum cephalosporin (1, 5, 9-1 1) is being studied for its use as chemotherapy against infections, the interpretive criteria proposed here should be considered. Furthermore, the value of these criteria for predicting the clinical or bacteriologic responses to FK-037 therapy should be correlated before the final interpretive breakpoints are adopted by national consensus agencies such as NCCLS. 
